-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

Benzinga·09/24/2026 12:02:24
Listen to the news
Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.